Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. VSports app下载.

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2015 Dec 1;33(34):4015-22.
doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.

"V体育官网入口" Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Junzo Hamanishi  1 , Masaki Mandai  2 , Takafumi Ikeda  2 , Manabu Minami  2 , Atsushi Kawaguchi  2 , Toshinori Murayama  2 , Masashi Kanai  2 , Yukiko Mori  2 , Shigemi Matsumoto  2 , Shunsuke Chikuma  2 , Noriomi Matsumura  2 , Kaoru Abiko  2 , Tsukasa Baba  2 , Ken Yamaguchi  2 , Akihiko Ueda  2 , Yuko Hosoe  2 , Satoshi Morita  2 , Masayuki Yokode  2 , Akira Shimizu  2 , Tasuku Honjo  2 , Ikuo Konishi  2
Affiliations
Clinical Trial

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

V体育官网入口 - Junzo Hamanishi et al. J Clin Oncol. .

Abstract

Purpose: Programmed death-1 (PD-1), a coinhibitory immune signal receptor expressed in T cells, binds to PD-1 ligand and regulates antitumor immunity VSports手机版. Nivolumab is an anti-PD-1 antibody that blocks PD-1 signaling. We assessed the safety and antitumor activity of nivolumab in patients with platinum-resistant ovarian cancer. .

Patients and methods: Twenty patients with platinum-resistant ovarian cancer were treated with an intravenous infusion of nivolumab every 2 weeks at a dose of 1 or 3 mg/kg (constituting two 10-patient cohorts) from October 21, 2011. This phase II trial defined the primary end point as the best overall response. Patients received up to six cycles (four doses per cycle) of nivolumab treatment or received doses until disease progression occurred. Twenty nivolumab-treated patients were evaluated at the end of the trial on December 7, 2014 V体育安卓版. .

Results: Grade 3 or 4 treatment-related adverse events occurred in eight (40%) of 20 patients. Two patients had severe adverse events. In the 20 patients in whom responses could be evaluated, the best overall response was 15%, which included two patients who had a durable complete response (in the 3-mg/kg cohort). The disease control rate in all 20 patients was 45%. The median progression-free survival time was 3. 5 months (95% CI, 1. 7 to 3. 9 months), and the median overall survival time was 20. 0 months (95% CI, 7 V体育ios版. 0 months to not reached) at study termination. .

Conclusion: This study, to our knowledge, is the first to explore the effects of nivolumab against ovarian cancer. The encouraging safety and clinical efficacy of nivolumab in patients with platinum-resistant ovarian cancer indicate the merit of additional large-scale investigations (UMIN Clinical Trials Registry UMIN000005714) VSports最新版本. .

PubMed Disclaimer

Comment in

Publication types

V体育安卓版 - MeSH terms

Associated data